Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

Published:2018-03 Issue: Volume:91 Page:92-98
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Schiefer Mart,Hendriks Lizza E.L.,Dinh Trang^ORCID,Lalji Ulrich^ORCID,Dingemans Anne-Marie C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. New and emerging targeted treatments in advanced non-small-cell lung cancer;Hirsch;Lancet,2016

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer;Soria;N Engl J Med,2018

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond;Frontiers in Pharmacology;2024-08-15

2. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

3. EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring;Frontiers in Oncology;2024-06-24

4. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer;Expert Opinion on Drug Safety;2023-12-13

5. Réanimation en oncologie thoracique;Revue des Maladies Respiratoires Actualités;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3